[PDF][PDF] Adherence to nucleos (t) ide analogue therapies for chronic hepatitis B infection: a systematic review and meta‐analysis
N Ford, R Scourse, M Lemoine, Y Hutin… - Hepatology …, 2018 - Wiley Online Library
Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high
levels of adherence to treatment. We searched three databases and abstracts from two …
levels of adherence to treatment. We searched three databases and abstracts from two …
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg‐positive chronic hepatitis B patients with high HBV DNA
L Gao, HN Trinh, J Li… - Alimentary pharmacology & …, 2014 - Wiley Online Library
Background Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the two first‐line
anti‐viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly …
anti‐viral therapies for chronic hepatitis B (CHB); however, there are limited studies directly …
Kinetics and prediction of HBsAg loss during long-term therapy with nucleos (t) ide analogues of different potency in patients with chronic hepatitis B
MR Li, HL Xi, QH Wang, FQ Hou, N Huo, XX Zhang… - PLoS …, 2014 - journals.plos.org
Background & Aims About 350–400 million people are infected with hepatitis B virus (HBV)
chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases …
chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases …
慢性乙型肝炎病毒感染者外周血T 细胞γ 干扰素和白细胞介素4 的水平变化
李曼， 孙学华， 周振华， 张鑫， 金树根， 高亚婷… - 细胞与分子免疫学 …, 2016 - cqvip.com
目的研究慢性乙型肝炎病毒(HBV) 感染过程中外周血T 细胞表达细胞因子的调节作用. 方法60
例慢性HBV 感染者分为免疫耐受期组, 免疫清除期组和非活动期组, 20 例健康人群作为对照组 …
例慢性HBV 感染者分为免疫耐受期组, 免疫清除期组和非活动期组, 20 例健康人群作为对照组 …
Alternative therapies for chronic hepatitis B patients with partial virological response to standard entecavir monotherapy
Background: Entecavir (ETV) is a first-line, oral antinucleoside agent for the treatment of
chronic hepatitis B patients. Despite its high potency, some patients may still be viremic after …
chronic hepatitis B patients. Despite its high potency, some patients may still be viremic after …
Dynamic characteristics of serum hepatitis B surface antigen in Chinese chronic hepatitis B patients receiving 7 years of entecavir therapy
XX Zhang, MR Li, HL Xi, Y Cao, RW Zhang… - Chinese Medical …, 2016 - mednexus.org
Background: The ultimate goal of hepatitis B treatment is hepatitis B surface antigen
(HBsAg) seroclearance. Several factors have been suggested to be associated with the rate …
(HBsAg) seroclearance. Several factors have been suggested to be associated with the rate …
Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy
Objectives It is unclear whether patients with chronic hepatitis B with partial response to
entecavir (ETV) who have achieved complete viral suppression (CVS) with ETV plus …
entecavir (ETV) who have achieved complete viral suppression (CVS) with ETV plus …
FACTORS ASSOCIATED WITH NON-ADHERENCE TO HEPATITIS B VIRUS ANTIVIRAL THERAPY
Objective: To assess the adherence to antivirals in Hepatitis B Virus (HBV) infected patients
and to determine various social and demographic factors which can have an impact on it …
and to determine various social and demographic factors which can have an impact on it …
Is increasing the dose of Entecavir effective in partial virological responders?
A Erturk, R Adnan Akdogan, E Parlak… - Drug Design …, 2014 - Taylor & Francis
Objective To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic
hepatitis B (CHB) who partially responded to ETV after 1 year. Methods Twenty-three …
hepatitis B (CHB) who partially responded to ETV after 1 year. Methods Twenty-three …